Galera Therapeutics, Inc. Income Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of operations

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating expenses:
Acquired in-process research and development
Research and development
General and administrative
Write-off of acquired intangible asset
Write-off of goodwill
Gain on litigation settlement
Restructuring costs
Loss from operations
Other income (expenses):
Interest income
Interest expense
Gain on extinguishment of debt
Gain on sale of dismutase mimetics assets
Change in fair value of warrant liability
Foreign currency loss
Income (loss) before income tax benefit
Income tax benefit
Net income (loss)
Net loss per share of common stock, basic
Net income (loss) attributable to common stockholders, basic
Series B Redeemable Convertible Preferred Stockholders
Total net income (loss) attributable to common stockholders, basic
Net loss per share of common stock, basic and diluted
Weighted-average shares of common stock outstanding, basic and diluted
Net income (loss) attributable to common stockholders, diluted
Series B Redeemable Convertible Preferred Stockholders
Total net income (loss) attributable to common stockholders, diluted
Net income (loss) per share of common stock, basic
Series B Redeemable Convertible Preferred Stock
Total net income (loss) per share of common stock, basic
Net income (loss) per share of common stock, diluted
Series B Redeemable Convertible Preferred Stock
Total net income (loss) per share of common stock, diluted
Weighted-average shares of common stock outstanding, basic
Series B Redeemable Convertible Preferred Stock
Total weighted-average shares of common stock outstanding, basic
Weighted-average shares of common stock outstanding, diluted
Series B Redeemable Convertible Preferred Stock
Total weighted-average shares of common stock outstanding, diluted

Comments